Prostate Cancer: From Drug Discover, Delivery to Resistance

Dear Colleagues,

Prostate cancer is one of the most common cancers in men globally. Its risk factors include age, family history of prostate cancer, certain genetic mutations, and race/ethnicity. Treatment options for prostate cancer depend on various factors, including the stage of the cancer, the aggressiveness of the tumor, the patient's overall health, and personal preferences. It often involves the use of drugs to target and control the growth of cancer cells.

This special issue focuses on the broad topic of drug treatment of prostate cancer. It covers the latest advancements in drug discovery, including the identification and development of novel therapeutic agents, molecular targets; drug delivery systems and approaches that enhance the efficacy, specificity, and safety of prostate cancer treatments, including topics such as nanomedicine, drug delivery carriers, targeted delivery systems, and localized drug delivery methods. In addition, we also pay attention to resistance mechanisms in prostate cancer, including both intrinsic and acquired resistance, the genetic, epigenetic, and microenvironmental factors contributing to treatment resistance in prostate cancer.

Dr. Siyoung Ha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• prostate cancer
• drug discovery
• drug delivery
• drug resistance
• anti-androgens
• targeted therapy